129 related articles for article (PubMed ID: 18710456)
1. Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?
Avery KN; Metcalfe C; Blazeby JM; Lane JA; Neal DE; Hamdy FC; Donovan JL
BJU Int; 2008 Dec; 102(11):1629-33. PubMed ID: 18710456
[TBL] [Abstract][Full Text] [Related]
2. Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
Collin SM; Metcalfe C; Donovan J; Lane JA; Davis M; Neal D; Hamdy F; Martin RM
BJU Int; 2008 Nov; 102(10):1400-6. PubMed ID: 18540932
[TBL] [Abstract][Full Text] [Related]
3. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
[TBL] [Abstract][Full Text] [Related]
4. Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial.
Avery KN; Blazeby JM; Lane JA; Neal DE; Hamdy FC; Donovan JL
Eur Urol; 2008 Jun; 53(6):1186-93. PubMed ID: 17709169
[TBL] [Abstract][Full Text] [Related]
5. Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy.
Avery KN; Metcalfe C; Vedhara K; Lane JA; Davis M; Neal DE; Hamdy FC; Donovan JL; Blazeby JM
Eur Urol; 2012 Oct; 62(4):649-55. PubMed ID: 22244151
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
Lane A; Metcalfe C; Young GJ; Peters TJ; Blazeby J; Avery KN; Dedman D; Down L; Mason MD; Neal DE; Hamdy FC; Donovan JL;
BJU Int; 2016 Dec; 118(6):869-879. PubMed ID: 27415448
[TBL] [Abstract][Full Text] [Related]
7. The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis.
Weight CJ; Kim SP; Jacobson DJ; McGree ME; Boorjian SA; Thompson RH; Leibovich BC; Karnes RJ; St Sauver J
Eur Urol; 2013 Jun; 63(6):1021-7. PubMed ID: 23313032
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
9. Association of lower urinary tract symptoms with sexual dysfunction: a cross-cultural study between Japanese and American men with localized prostate cancer.
Namiki S; Litwin MS; Kwan L; Kagawa-Singer M; Ishidoya S; Saito S; Arai Y
BJU Int; 2009 Oct; 104(8):1071-6. PubMed ID: 19519765
[TBL] [Abstract][Full Text] [Related]
10. Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial.
Evans R; Joseph-Williams N; Edwards A; Newcombe RG; Wright P; Kinnersley P; Griffiths J; Jones M; Williams J; Grol R; Elwyn G
J Med Internet Res; 2010 Aug; 12(3):e27. PubMed ID: 20693148
[TBL] [Abstract][Full Text] [Related]
11. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS.
Coyne KS; Wein AJ; Tubaro A; Sexton CC; Thompson CL; Kopp ZS; Aiyer LP
BJU Int; 2009 Apr; 103 Suppl 3():4-11. PubMed ID: 19302497
[TBL] [Abstract][Full Text] [Related]
12. The role of BPH, lower urinary tract symptoms, and PSA levels on erectile function of Brazilian men who undergo prostate cancer screening.
Antunes AA; Srougi M; Dall'oglio MF; Vicentini F; Paranhos M; Freire GC
J Sex Med; 2008 Jul; 5(7):1702-7. PubMed ID: 18194186
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of lower urinary tract symptoms and prostate enlargement in the primary care setting.
Naslund MJ; Gilsenan AW; Midkiff KD; Bown A; Wolford ET; Wang J
Int J Clin Pract; 2007 Sep; 61(9):1437-45. PubMed ID: 17686091
[TBL] [Abstract][Full Text] [Related]
14. Screening by lower urinary tract symptoms vs asymptomatic prostate-specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome.
Borre M
BJU Int; 2009 Jul; 104(2):205-8. PubMed ID: 19154477
[TBL] [Abstract][Full Text] [Related]
15. Detection rate of prostate cancer using prostate specific antigen in patients presenting with lower urinary tract symptoms: a retrospective study.
Chavan PR; Chavan SV; Chavan NR; Trivedi VD
J Postgrad Med; 2009; 55(1):17-21. PubMed ID: 19242073
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic value of abdominal ultrasound, urine cytology and prostate-specific antigen testing in the lower urinary tract symptoms clinic.
Patel NS; Blick C; Kumar PV; Malone PR
Int J Clin Pract; 2009 Dec; 63(12):1734-8. PubMed ID: 19930334
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer testing in SA men: influence of sociodemographic factors, health beliefs and LUTS.
Weller D; Pinnock C; Silagy C; Hiller JE; Marshall VR
Aust N Z J Public Health; 1998; 22(3 Suppl):400-2. PubMed ID: 9629831
[TBL] [Abstract][Full Text] [Related]
18. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.
Paranhos M; Antunes A; Andrade E; Freire G; Srougi M
BJU Int; 2009 Oct; 104(8):1130-3. PubMed ID: 19426190
[TBL] [Abstract][Full Text] [Related]
19. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg Randomized Screening Trial.
Frånlund M; Carlsson S; Stranne J; Aus G; Hugosson J
BJU Int; 2012 Sep; 110(5):638-43. PubMed ID: 22540895
[TBL] [Abstract][Full Text] [Related]
20. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
Lehrer S; Cesaretti J; Stone NN; Stock RG
BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
